

FROM

(WED) 5. 1'02 10:32/ST. 10:30/NO. 4865014896 P 6
1102803-0030

IN THE CLAIMS:

Please cancel claims 1 -34 without prejudice, and consider the following new claims:

sub C27
--35. An immunogenic composition formulated as an emulsion which is stable in cold storage comprising an aqueous immunogen and a pharmaceutically acceptable oily vehicle comprising a suitable squalene or a suitable mixture of squalene and squalane.

--36. The immunogenic composition as claimed in claim 35, wherein the cold storage comprises a freezing temperature.

--37. The immunogenic composition as claimed in claim 35, wherein the cold storage comprises a temperature of 4°C.

sub C37
B1
--38. The immunogenic composition as claimed in claim 36, wherein the emulsion is formulated as a mixture of the oily vehicle and the aqueous immunogen so as to form an oil-in-water or water-in-oil emulsion.

--39. The immunogenic composition as claimed in claim 37, wherein the oily vehicle is selected from the group consisting of the Montanide type ISA 25, ISA 28D, ISA 206, ISA 206D, ISA 703 and ISA 720, and SBAS3.

sub C4
--40. The immunogenic composition as claimed in claim 36, wherein the oily vehicle is selected from the group consisting of the Montanide type ISA 25, ISA 703, ISA 719 and ISA 720.

--41. The immunogenic composition as claimed in claim 36, wherein the cold storage can last at least one year.

--42. The immunogenic composition as claimed in claim 37, wherein the cold storage can last at least 8 days.

--43. The immunogenic composition as claimed in claim 35, wherein the aqueous immunogen comprises a gastrin-17 (G17), a gastrin-34 (G34), or gonadotropin releasing hormone immunomimic peptide conjugated to an immunogenic carrier protein optionally linked through a spacer peptide.

Sub C5
--44. The immunogenic composition as claimed in claim 36 or claim 43, wherein the composition exhibits increased immunogenicity upon storage.

--45. A method for formulating an immunogenic composition suitable for cold storage comprising:

preparing an immunogenic emulsion comprising mixing an aqueous immunogen with a pharmaceutically acceptable oily vehicle in an oil-in-water or water-in-oil formulation, wherein the suitable oily vehicle is selected for the group consisting of a SBAS3 and a Montanide type ISA 25, ISA 28D, ISA 206, ISA 206D, ISA 703, and ISA 720.

B1
--46. The method as claimed in claim 45, wherein the immunogenic comprises a hormone-immunomimic peptide or an effective fragment thereof combined with an immunogenic component.

--47. The method as claimed in claim 46, wherein the hormone is selected from the group consisting of gastrin G17, gastrin G34, and GnRH.

Sub C6
--48. A method for formulating an immunogenic emulsion stable in cold storage at freezing temperature comprising:

preparing an immunogenic emulsion by mixing an aqueous immunogen comprising a compound having an immunogenic portion and an immunomimic portion with a pharmaceutically acceptable oily vehicle as a stable storage oil-in-water or water-in-oil

FROM

(WED) 5. 1'02 10:32/ST. 10:30/NO. 4865014896 P 8

formulation, wherein the oily vehicle is selected from the group consisting of a Montanide type ISA 25, ISA 703, ISA 719 and ISA 720.

cont
B1
--49. The method as claimed in claim 45 or 48, wherein the storage stability of the immunogenic emulsion comprises a prolonged integrity of the immunogen.

--50. The method as claimed in claim 49, wherein the integrity is preserved for more than one week.

--51. The method as claimed in claim 49, wherein the integrity is preserved for more than one month.

--52. The method as claimed in claim 49, wherein the integrity is preserved for more than one year.

REMARKS

Consideration of the preliminary amendment is requested. Original claims 1-34 have been cancelled without prejudice. New claims 35-52 have been newly added for examination. No new subject matter has been added with the new claims, which are fully supported by the specification.